These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 35034552)
1. Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia. Liu Y; Li H; Zhao Y; Li D; Zhang Q; Fu J; Fan S Bioengineered; 2022 Feb; 13(2):2296-2307. PubMed ID: 35034552 [TBL] [Abstract][Full Text] [Related]
2. LncRNA OIP5-AS1 Promotes the Autophagy-Related Imatinib Resistance in Chronic Myeloid Leukemia Cells by Regulating miR-30e-5p/ATG12 Axis. Dai H; Wang J; Huang Z; Zhang H; Wang X; Li Q; Feng W Technol Cancer Res Treat; 2021; 20():15330338211052150. PubMed ID: 34723728 [No Abstract] [Full Text] [Related]
3. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia. Wen F; Cao YX; Luo ZY; Liao P; Lu ZW Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670 [TBL] [Abstract][Full Text] [Related]
4. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis. Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164 [TBL] [Abstract][Full Text] [Related]
5. Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells. Liu Z; Zheng W; Liu Y; Zhou B; Zhang Y; Wang F Exp Cell Res; 2021 Aug; 405(2):112708. PubMed ID: 34157313 [TBL] [Abstract][Full Text] [Related]
6. LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis. Han Y; Ma Z Anticancer Drugs; 2021 Apr; 32(4):427-436. PubMed ID: 33587348 [TBL] [Abstract][Full Text] [Related]
7. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells. Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of Deng Y; Li X; Feng J; Zhang X Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564 [TBL] [Abstract][Full Text] [Related]
9. GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia. Han SH; Korm S; Han YG; Choi SY; Kim SH; Chung HJ; Park K; Kim JY; Myung K; Lee JY; Kim H; Kim DW Autophagy; 2019 Dec; 15(12):2076-2090. PubMed ID: 30929559 [TBL] [Abstract][Full Text] [Related]
10. MiRNA-409-5p dysregulation promotes imatinib resistance and disease progression in children with chronic myeloid leukemia. Liu YY; Jiao WY; Li T; Bao YY Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8468-8475. PubMed ID: 31646577 [TBL] [Abstract][Full Text] [Related]
11. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib. Yandim MK; Ceylan C; Elmas E; Baran Y Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734 [TBL] [Abstract][Full Text] [Related]
12. Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells. Zhang J; Zhang M; Liang Y; Liu M; Huang Z Hematology; 2022 Dec; 27(1):43-52. PubMed ID: 34957936 [No Abstract] [Full Text] [Related]
13. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells. Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182 [TBL] [Abstract][Full Text] [Related]
14. The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells. Zeng C; Liu S; Lu S; Yu X; Lai J; Wu Y; Chen S; Wang L; Yu Z; Luo G; Li Y Mol Cancer; 2018 Aug; 17(1):130. PubMed ID: 30153828 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133 [TBL] [Abstract][Full Text] [Related]
16. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells. Wang XY; Sun GB; Wang YJ; Yan F Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163 [TBL] [Abstract][Full Text] [Related]
17. Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia. Li W; Ji M; Lu F; Pang Y; Dong X; Zhang J; Li P; Ye J; Zang S; Ma D; Ji C Cell Death Dis; 2018 Aug; 9(9):855. PubMed ID: 30154435 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5. Jiang X; Cheng Y; Hu C; Zhang A; Ren Y; Xu X Leuk Lymphoma; 2019 Jul; 60(7):1709-1720. PubMed ID: 30516071 [TBL] [Abstract][Full Text] [Related]
19. LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of chronic myeloid leukemia cells by sponging with micRNA-1275. Yang JR; Shi MX; Zeng Y Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2103-2111. PubMed ID: 30915755 [TBL] [Abstract][Full Text] [Related]
20. p19 Kuang Y; Han X; Cao P; Xiong D; Peng Y; Liu Z; Xu Z; Liang L; Roy M; Liu J; Nie L; Zhang J Blood Cells Mol Dis; 2020 Nov; 85():102477. PubMed ID: 32711219 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]